Datapoint: Jakafi Approved for Chronic GVHD

The FDA last week approved Incyte Corp.’s JAK inhibitor Jakafi for the treatment of chronic graft-versus-host disease (GVHD) in patients that have not responded to one or two other lines of systemic therapy. Jakafi, which is already approved for the acute form of the disease, currently holds covered or better status for 70% of all insured lives.

SOURCE: MMIT Analytics, as of 9/23/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 29

Datapoint: Optum Rx to Launch New Drug Pricing Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 28

Datapoint: Point32Health Offers In-Home Urgent Care

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Centene Pledges Nearly $1B for Affordable Housing

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today